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No Postage Required: Extracellular Vesicles Deliver the Message 1 
[an Editorial for the Theme “Extracellular Vesicles in Cell Physiology”] 2 
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Extracellular vesicles (EVs) were first appreciated when electron microscopists 24 
illuminated the structure of cells and the materials they released into the extracellular space (9). 25 
However, the number of publications related to EVs hovered below two hundred per year from 26 
the late 1970’s until 2008. The last 10 years have witnessed a 10- to 20-fold increase in the 27 
number of publications on EVs per year.  28 
The ability of these structures to capture the attention of scientists comes, in part, from 29 
the important roles in cell communication they have been found to play and the diverse array of 30 
processes they are involved in. EVs are ubiquitous to life and are made by uni- and multi-cellular 31 
life forms including eukaryotes such as yeast (6) and parasites and prokaryotes such as bacteria 32 
and archaea (3). Also, viruses interact with EVs, and EVs appear to utilize viral cell entry 33 
pathways to cells (10). Thus, EVs are a highly conserved cellular adaptation, and eukaryotic 34 
organisms share proteins that regulate EV formation such as the endosomal sorting complexes 35 
required for transport (4). EVs originate by direct cell membrane budding or from intracellularly 36 
generated bodies containing multiple vesicles that fuse with the cell membrane. In either 37 
mechanism, the EVs escape into the extracellular space and have potential to bind local or distant 38 
cells. While details of these biogenic pathways have been described (1), it is likely that other 39 
mechanisms remain to be discovered. EVs are packed with a range of bio-reactive materials 40 
including several forms of RNA, mitochondria (5), lipids, enzymes, second messenger cyclic 41 
nucleotides (8), and metabolites, which are released by EVs, upon membrane fusion, into the 42 
cytoplasm of target cells. Further, EVs are decorated with proteins that reflect the surface 43 
expression of the parent cells (7) suggesting that EVs may signal by intersecting with established 44 
ligand-receptor mechanisms. 45 
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 As with any burgeoning area of scientific investigation, the EV field has suffered from 46 
confusion in terminology, classification, methods of isolation and preparation and a paucity of 47 
details in experimental protocols, amongst other things. This has resulted in heterogeneity in 48 
published findings and little experimental reproducibility. Stimulated by a number of EV-49 
focused professional groups and publications, progress is being made in correcting these 50 
deficiencies. Efforts to standardize definitions and terms, harvesting and processing protocols, 51 
and the application of the same to GMP programs is being made. This is needed given the 52 
expanding number of EV-focused clinical trials. A recent search of ClincalTrials.gov employing 53 
the term ‘extracellular vesicles’ identified at least a dozen trials. The identified trials explore the 54 
biology, biomarker and therapeutic applications of EVs.  55 
 56 
 Consideration of issues surrounding EV research design, reporting and clinical trials 57 
highlights areas for improvement:  58 
  In vivo demonstration of EV formation, movement, lodgment and uptake should be 59 
undertaken. A strategy to characterize the in vivo physiologic and pathologic parameters 60 
that govern EV activities over the life cycle is paramount. This is necessary if any 61 
therapeutic potential is to be realized.  62 
 Activities of EVs upon established non-EV signaling pathways need to be tested. As a 63 
‘Johnny come lately’ field within the cell biology realm, there are important questions on 64 
what aspects of canonical cell signaling are impacted by EV-related mechanisms. Do 65 
EVs shape canonical ligand-receptor interactions or vice versa? What parameters set the 66 
playing field: that is, which signaling mechanism dominates under physiological 67 
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conditions? Do therapies/drugs that target standard ligand-receptor interactions alter EV 68 
signaling and do EVs alter the therapeutic effect of these drugs? 69 
 In relation to further research, the most appropriate EV-relevant control agents and 70 
parameters/standards need to be identified and initiated in cell and animal studies.    71 
 Further enquiries into the interaction between EVs and other agents administered to cell 72 
cultures will likely prove of interest. In this regard, could EVs be accountable (in part) for 73 
variability in standard cell culture experimental designs? As a ‘contaminant’ in a biologic 74 
preparation, do they hitch a ride and either direct or modify the outcomes as an 75 
unaccounted component of agents given to cells or whole organisms? Can we be sure that 76 
other GMP-produced biologics do not include EVs that survive the production process? 77 
Thus, could the therapeutic result of these biologics be (at least in part) an effect of EVs? 78 
 As government bodies continue to receive clinical trial requests from academic and 79 
industry teams seeking to determine whether EVs have healing properties, a step back 80 
may be reasonable. Large, well-controlled and blinded clinical studies looking to 81 
determine associative, causative, or contributive niches held by EVs in diseases, trauma 82 
and health should be started with translation across ethnic, economic and geographic 83 
boundaries.  GMP production and clinical study minimum guidelines should be 84 
determined and invoked.  85 
 Also important for future research and publications would be the development of rigorous 86 
isolation, identification, characterization and confirmative protocols agreed upon by an 87 
international consensus of researchers and governmental bodies with sustained activity in 88 
the EV field. These can then be promulgated and accepted by major scientific bodies and 89 
journals. As major international scientific publishers have established and aligned 90 
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themselves behind a minimum threshold of scientific consistency in general methods and 91 
reporting, this rigor should also be applied to reporting of EVs. Unification of 92 
terminology and classification of EV and EV-associated particles into categories defined 93 
by physical properties and mode of genesis should be achieved in oral and written 94 
scholarly communications. Although future discoveries may require revision of the initial 95 
organizational/classification systems, starting a discussion soon will be of value. The 96 
current arbitrary aspects have opened up the field to constant criticism and made 97 
objective interpretation of data daunting. Addressing these matters fits well with the 98 
laudable efforts to improve scientific rigor, transparency and reproducibility in general 99 
and especially in the physiological sciences, in which the American Physiological Society 100 
is playing an active part.  101 
 102 
Biologics have a ‘favored child’ position in the therapeutic realm and for individuals may 103 
provide treatment for what were previously undruggable diseases. EVs are passively benefiting 104 
from the special accommodations currently afforded biologics (e.g. stem cells). However, until 105 
defined classification, processing, and validation issues are resolved, any benefits ascribed will 106 
likely be associative.   107 
In the present Theme on “Extracellular Vesicles in Cell Physiology” the current state of EV 108 
research is reviewed by a number of leading groups with a focus on EV involvement in the areas 109 
of stem cell biology, leukemia, and tumor progression. In this issue, the Theme begins with a 110 
Review by Dr. Borgovan and colleagues on EVs in leukemia (2).  111 
The Editors of the American Journal of Physiology - Cell Physiology thank all of the authors 112 
for their time and effort in contributing these excellent Reviews. We hope that readers will find 113 
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these articles of interest and a stimulus to consider the possible roles of EVs in their own 114 
experimental systems. We cordially invite all investigators to submit research articles for a Call 115 
for Papers on “Extracellular Vesicles in Cell Physiology” which will open for submissions on 116 
June 1, 2019. 117 
 118 
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